Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06447623 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Name: Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer — clinical trial record (NCT06447623)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 3

SponsorFudan University

Started2024-06-11

View on ClinicalTrials.gov ↗

Amendment history

2026-09-26

Enrollment closed, study ongoing

Fudan University

624 trials monitored

See 9 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This is a randomized, controlled, open-label, phase III study to explore the efficacy and safety of Apatinib in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF4 subtype of advanced breast cancer. The study was used to explore the efficacy of Apatinib in combination with standard endocrine therapy.

Trial Details

NCT Number	NCT06447623
Lead Sponsor	Fudan University
Conditions	Advanced Breast Cancer, HR+/HER2- Breast Cancer
Enrollment	184 participants
Start Date	2024-06-11
Primary Completion	2027-02-01 (estimated)
Study Completion	2029-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-25